CN108618129A - 肌肉衰减综合症专用型临床营养配方及其制备方法 - Google Patents
肌肉衰减综合症专用型临床营养配方及其制备方法 Download PDFInfo
- Publication number
- CN108618129A CN108618129A CN201810444528.6A CN201810444528A CN108618129A CN 108618129 A CN108618129 A CN 108618129A CN 201810444528 A CN201810444528 A CN 201810444528A CN 108618129 A CN108618129 A CN 108618129A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- sarcopenia
- vitamin
- clinical nutrition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 56
- 208000001076 sarcopenia Diseases 0.000 title claims abstract description 52
- 230000035764 nutrition Effects 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000009472 formulation Methods 0.000 title claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- 235000013305 food Nutrition 0.000 claims abstract description 30
- 229940088594 vitamin Drugs 0.000 claims abstract description 29
- 229930003231 vitamin Natural products 0.000 claims abstract description 29
- 235000013343 vitamin Nutrition 0.000 claims abstract description 29
- 239000011782 vitamin Substances 0.000 claims abstract description 29
- 230000035622 drinking Effects 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000008216 herbs Nutrition 0.000 claims abstract description 22
- 230000010354 integration Effects 0.000 claims abstract description 22
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 19
- 235000005911 diet Nutrition 0.000 claims abstract description 17
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 15
- 230000037213 diet Effects 0.000 claims abstract description 15
- 239000004615 ingredient Substances 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 8
- 239000011573 trace mineral Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims description 97
- 235000013350 formula milk Nutrition 0.000 claims description 39
- 235000018102 proteins Nutrition 0.000 claims description 35
- 235000015097 nutrients Nutrition 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 26
- 150000005693 branched-chain amino acids Chemical class 0.000 claims description 23
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 235000019197 fats Nutrition 0.000 claims description 21
- 235000001014 amino acid Nutrition 0.000 claims description 20
- 241000196324 Embryophyta Species 0.000 claims description 18
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 18
- 235000010755 mineral Nutrition 0.000 claims description 18
- 239000011707 mineral Substances 0.000 claims description 18
- 229920001503 Glucan Polymers 0.000 claims description 17
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 15
- 235000014633 carbohydrates Nutrition 0.000 claims description 14
- 229920002774 Maltodextrin Polymers 0.000 claims description 13
- 239000005913 Maltodextrin Substances 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 13
- 230000003301 hydrolyzing effect Effects 0.000 claims description 13
- 229940035034 maltodextrin Drugs 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 12
- 235000010489 acacia gum Nutrition 0.000 claims description 9
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 9
- 235000019198 oils Nutrition 0.000 claims description 9
- 235000004347 Perilla Nutrition 0.000 claims description 8
- 244000124853 Perilla frutescens Species 0.000 claims description 8
- 239000003240 coconut oil Substances 0.000 claims description 8
- 235000019864 coconut oil Nutrition 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 8
- 239000004006 olive oil Substances 0.000 claims description 8
- 235000008390 olive oil Nutrition 0.000 claims description 8
- 239000003549 soybean oil Substances 0.000 claims description 8
- 235000012424 soybean oil Nutrition 0.000 claims description 8
- 241000206575 Chondrus crispus Species 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000011162 core material Substances 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 235000010419 agar Nutrition 0.000 claims description 5
- 239000004519 grease Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 4
- 240000003183 Manihot esculenta Species 0.000 claims description 4
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 4
- 108010001441 Phosphopeptides Proteins 0.000 claims description 4
- 108010073771 Soybean Proteins Proteins 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 4
- 229940029339 inulin Drugs 0.000 claims description 4
- -1 is uniformly mixed Substances 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 235000019710 soybean protein Nutrition 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 241000208688 Eucommia Species 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 229940099112 cornstarch Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000020243 first infant milk formula Nutrition 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 150000002213 flavones Chemical class 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 241000219780 Pueraria Species 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000019871 vegetable fat Nutrition 0.000 claims description 2
- 241000220324 Pyrus Species 0.000 claims 1
- 235000021017 pears Nutrition 0.000 claims 1
- 238000011084 recovery Methods 0.000 abstract description 6
- 210000003205 muscle Anatomy 0.000 description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
- 201000010099 disease Diseases 0.000 description 37
- 230000006870 function Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 17
- 239000000835 fiber Substances 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- 235000005772 leucine Nutrition 0.000 description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 241000219784 Sophora Species 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 210000002027 skeletal muscle Anatomy 0.000 description 12
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 12
- 241000234435 Lilium Species 0.000 description 11
- 244000246386 Mentha pulegium Species 0.000 description 11
- 235000016257 Mentha pulegium Nutrition 0.000 description 11
- 235000004357 Mentha x piperita Nutrition 0.000 description 11
- 210000004317 gizzard Anatomy 0.000 description 11
- 235000001050 hortel pimenta Nutrition 0.000 description 11
- 230000003387 muscular Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 235000015459 Lycium barbarum Nutrition 0.000 description 10
- 244000241838 Lycium barbarum Species 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229960005069 calcium Drugs 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 229930003316 Vitamin D Natural products 0.000 description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 235000019166 vitamin D Nutrition 0.000 description 8
- 239000011710 vitamin D Substances 0.000 description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 description 8
- 229940046008 vitamin d Drugs 0.000 description 8
- 229920000294 Resistant starch Polymers 0.000 description 7
- 229930003427 Vitamin E Natural products 0.000 description 7
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 7
- 235000013734 beta-carotene Nutrition 0.000 description 7
- 239000011648 beta-carotene Substances 0.000 description 7
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 7
- 229960002747 betacarotene Drugs 0.000 description 7
- 230000037182 bone density Effects 0.000 description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 235000021254 resistant starch Nutrition 0.000 description 7
- 239000013589 supplement Substances 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 235000019165 vitamin E Nutrition 0.000 description 7
- 239000011709 vitamin E Substances 0.000 description 7
- 229940046009 vitamin E Drugs 0.000 description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 108010038807 Oligopeptides Proteins 0.000 description 6
- 102000015636 Oligopeptides Human genes 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 235000021277 colostrum Nutrition 0.000 description 6
- 210000003022 colostrum Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 235000019688 fish Nutrition 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 229960003512 nicotinic acid Drugs 0.000 description 6
- 235000001968 nicotinic acid Nutrition 0.000 description 6
- 239000011664 nicotinic acid Substances 0.000 description 6
- 229940055726 pantothenic acid Drugs 0.000 description 6
- 235000019161 pantothenic acid Nutrition 0.000 description 6
- 239000011713 pantothenic acid Substances 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 229960003080 taurine Drugs 0.000 description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 6
- 235000019155 vitamin A Nutrition 0.000 description 6
- 239000011719 vitamin A Substances 0.000 description 6
- 239000011691 vitamin B1 Substances 0.000 description 6
- 239000011715 vitamin B12 Substances 0.000 description 6
- 239000011716 vitamin B2 Substances 0.000 description 6
- 239000011726 vitamin B6 Substances 0.000 description 6
- 239000011647 vitamin D3 Substances 0.000 description 6
- 229940045997 vitamin a Drugs 0.000 description 6
- 235000008939 whole milk Nutrition 0.000 description 6
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 235000013372 meat Nutrition 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- 208000037581 Persistent Infection Diseases 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000003132 food thickener Nutrition 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 244000075850 Avena orientalis Species 0.000 description 3
- 235000007319 Avena orientalis Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 229920002752 Konjac Polymers 0.000 description 3
- 102000008934 Muscle Proteins Human genes 0.000 description 3
- 108010074084 Muscle Proteins Proteins 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000024244 muscle cell apoptotic process Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000015816 nutrient absorption Nutrition 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 102000009310 vitamin D receptors Human genes 0.000 description 3
- 108050000156 vitamin D receptors Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 2
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 240000002547 Rosa roxburghii Species 0.000 description 2
- 235000000640 Rosa roxburghii Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000000252 konjac Substances 0.000 description 2
- 235000010485 konjac Nutrition 0.000 description 2
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 230000037257 muscle growth Effects 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 240000005717 Dioscorea alata Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 206010016352 Feeling of relaxation Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 240000001740 Momordica dioica Species 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 241000287420 Pyrus x nivalis Species 0.000 description 1
- 102000016983 Releasing hormones receptors Human genes 0.000 description 1
- 108070000025 Releasing hormones receptors Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 108010079452 beta Adrenergic Receptors Chemical class 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 1
- 229960001023 tibolone Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pediatric Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供一种肌肉衰减综合症专用型临床营养配方,包括如下组分及其重量份数:18‑30份蛋白质、9‑13份脂肪、40‑52份碳水化合物、4‑8份膳食纤维、0.6‑1.2份常量元素、0.01‑0.03份微量元素、0.005‑0.02份脂溶性维生素、0.005‑0.20份水溶性维生素、0.2‑1份膳***华、0.07‑4份药食同源成分、0.1‑1份天然植物化合物以及0.03‑0.6份新资源食品;本发明还提供上述临床营养配方的制备方法。本发明的临床营养配方能够满足肌肉衰减综合症患者全面均衡的营养需求,又能够改善肌肉衰减综合症患者的身体质量,促进肌力恢复和肌肉再生。
Description
技术领域
本发明涉及营养配方领域,尤其涉及一种肌肉衰减综合症专用型临床营养配方及其制备方法。
背景技术
肌肉骨骼***在保持***、完成运动、保护重要内脏器官及机体内环境稳态等方面发挥着重要作用。肌肉与骨骼不仅位置毗邻、功能相辅,而且受到神经、内分泌、免疫、营养、力学刺激的***性调节,以及两者间内分泌、旁分泌和机械力学的局部相互调节。此外,骨骼和肌肉间还存在某些相似的分子信号调节通路,这些调节通路的分子信号有望成为干预的共同靶点。
随着社会人口老龄化,肌肉骨骼疾病已经成为重要的公共健康问题。肌肉减少症(sarcopenia,简称肌少症)、骨质疏松症(osteoporosis)和骨折的发生率均随增龄而增加,肌少症和骨质疏松症相伴出现被统称为“活动障碍综合症”(dysmobility syndrome),“活动障碍综合症”会致使老年人易于跌倒和骨折,继而成为老年人群致残、致死的主要原因之一。与骨质疏松症相比,肌少症近10年来才逐渐受到重视,并在基础和临床研究方面取得了重要进展,国外相关学会相继颁布了肌少症的临床指南。
肌肉衰减综合症是一种特征为骨骼肌肉质量降低和骨骼肌肌力下降的病症,并伴随病人残疾和死亡的风险、生活质量明显下降。流行病学研究显示,人体骨骼肌随年龄增加不断衰减。据报道一般50岁以后,骨骼肌量平均每年减少1%~2%,60岁以上慢性肌肉丢失估计30%,80岁以上丢失约50%,而肌肉减少30%将影响肌肉正常功能。美国与欧洲的报道显示,患肌肉衰减症者,60岁~70岁老年人中占5%~13%,80岁以上增加至11%~52%。
肌少症是增龄相关疾病,是环境和遗传因素共同作用的复杂疾病,多种风险因素和机制参与其发生,肌少症的发病机制涉及如下多个方面:
运动减少:增龄相关的运动能力下降是老年人肌肉量和强度丢失的主要因素。长期卧床者肌肉强度的下降要早于肌肉量的丢失,活动强度不足导致肌力下降,而肌肉无力又使活动能力进一步降低,最终肌肉量和肌肉强度均下降。较多研究提示老年人进行阻抗运动能显著增加肌肉量、肌肉强度和肌肉质量。
神经-肌肉功能减弱:运动神经元的正常功能对肌纤维的存活是必需的,在肌少症发病机制中α运动神经元的丢失是关键因素,研究发现老年人70岁以后运动神经元数量显著减少,α运动神经元丢失达50%,显著影响下肢功能。老年时期α运动神经元和运动单元数量的显著减少直接导致肌肉协调性下降和肌肉强度的减弱。在肌肉纤维数量上,对成人肌肉的研究发现,90岁时肌肉中Ⅰ型和Ⅱ型纤维含量仅为年轻人的一半。老年时期,由于星状细胞数量和募集能力下降,导致Ⅱ型纤维比Ⅰ型纤维下降更显著。星状细胞是肌源性干细胞,可在再生过程中被激活,分化为新肌纤维和新星状细胞,但是这种再生过程在应对损伤时将导致Ⅱ型纤维不平衡和数量减少,且老年人肌肉更易损和难修复。
增龄相关激素变化:胰岛素、***、雄激素、生长激素和糖皮质激素等的变化参与肌少症的发病。肌少症时,身体和肌细胞内脂肪增加,这与胰岛素抵抗有关。实验已证实老化肌细胞接受胰岛素作用后,蛋白生成能力明显降低。***对肌少症的发病作用存在不一致的证据,一些流行病学和干预研究提示***可以预防肌肉量的丢失。对5项随机对照临床试验进行的***分析,3项研究表明***替代治疗后肌肉强度增加,但不影响身体成分分布,一项研究表明替勃龙增加股四头肌和膝伸直肌强度,且增加瘦组织量、降低体脂量。一项对健康、老化和身体成分的研究,发现***替代治疗后,股四头肌横断面面积更高,但与膝伸直肌强度无关。可见,***主要影响肌肉强度,在肌少症发病中可能不是最重要的因素。而男性睾酮水平随增龄每年下降1%,这在男性肌少症发病中起重要作用。很多研究显示老年男性低睾酮水平与肌肉量、强度和功能的下降均相关,体外实验也证实睾酮可剂量依赖地促进星状细胞数量增加,且是其功能的主要调控因子。此外,老年人维生素D缺乏非常普遍,多项研究证实维生素D缺乏是肌少症的风险因素,并且1,25双羟维生素D水平降低与肌肉量、肌肉强度、平衡力下降和跌倒风险增加相关。
促炎性反应细胞因子:促炎性反应细胞因子参与老年人肌少症的发病,研究发现血IL-6、TNF-α和C反应蛋白水平与肌肉量、肌肉强度有关。荷兰老年人群的研究提示高水平IL-6和C反应蛋白使肌肉量和肌肉强度丢失风险增加。这些炎性反应细胞因子增高引起肌肉组织合成代谢失衡,蛋白分解代谢增加。老年人炎性反应细胞因子长期增高是肌少症的重要危险因素。
肌细胞凋亡:肌肉活检显示老年人肌细胞凋亡显著高于年轻人,这是肌少症的基本发病机制,肌细胞凋亡与线粒体功能失常和肌肉量丢失有关。研究证实肌少症主要累及的Ⅱ型肌纤维更容易通过凋亡途径而死亡。增龄、氧化应激、低生长因子以及完全制动等可触发Caspase依赖或非依赖的凋亡信号通路。
遗传因素:遗传因素可以分别解释个体间肌肉强度、下肢功能和日常生活能力变异的36%~65%、57%和34%。肌少症的全基因组关联分析(GWAS)数据较少,2009年对1000例无亲缘关系美国白人进行的GWAS与瘦组织分析,发现甲状腺释放激素受体(TRHR)单核苷酸多态性(SNP)rs16892496和rs7832552与瘦组织变异有关。
营养因素:已证实老年人合成代谢率降低30%,其降低究竟与老年人营养、疾病、活动少有关,还是仅与增龄有关,仍有争议。老年人营养不良和蛋白质摄入不足可致肌肉合成降低,已有研究证实氨基酸和蛋白补充可直接促进肌肉蛋白合成,预防肌少症,推荐合适的饮食蛋白摄入量为每天每千克体质量1.0~1.2g。
肌少症缺乏特异的临床表现,患者可表现为虚弱、容易跌倒、行走困难、步态缓慢、四肢纤细和无力等,其诊断有赖于肌力、肌强度和肌量的评估等方面。
肌少症的防治对象包括所有的肌少症人群,包括各种疾病、药物和废用等所致的肌少症和老年性肌少症。防治措施包括运动疗法、营养疗法和药物治疗。运动疗法的益处与其经抗氧化反应等途径缓解细胞衰老等有关。有氧运动和抗阻训练均能减少随着年龄增加的肌肉质量和肌肉力量的下降。抗阻训练被认为是对骨骼肌减少症一种最好的非药物干预方式之一。研究表明,高强度抗阻锻炼较低中强度抗阻锻炼更能显著提高肌量和肌力。但高强度抗阻训练可增加老年人受伤概率,过度的运动能增加心脏病发病的风险,甚至引起猝死。
目前还没有以肌少症为适应证的药物,临床上治疗其他疾病的部分药物可能使肌肉获益,进而推广用于肌少症。其中包括合成类激素、活性维生素D、β肾上腺能受体激动剂、血管紧张素转换酶抑制剂、肌肉生长抑制因子的抗体及激活素受体激动剂等。
由于大多数老年人存在热量和蛋白质摄入不足,因此建议老年人在日常生活中要保持平衡膳食和充足营养。如果饮食中营养不足,或存在其他过度消耗因素时,应考虑蛋白质或氨基酸营养补充治疗。数项研究证实在足够营养的基础上,配合运动治疗可以增加肌量和肌强度。充足的蛋白摄入(1~1.2g/kg·d)亦可以提高肌量和部分肌肉功能。特别是富含亮氨酸等必需氨基酸的乳清蛋白。补充必需氨基酸可能预防由于长期卧床引起的肌量减少。
肌少症的发病率越来越高,很多因素均可导致或加重其发生、发展,它们之间相互作用、联系紧密,且无明确分界线,其中年龄是最重要的因素。对于肌少症的防治,尤其是老年性肌少症的防治,应该从多方面进行,不能针对某一独立的因素,这样才能有效降低发病率,减少老年患者的跌倒及骨折风险。其中营养干预是预防和治疗老年人肌少症的有效途径之一。
但目前除了运动疗法外,相应的药物治疗和营养治疗很少有专门针对肌肉衰减症患者的产品。
中国专利CN201410402199.0公开了一种肌肉衰减综合征全营养配方食品,其“消中寓补”、“均衡调养”的传统中医的精髓理论,采用4种以上药食两用的中药提取物精华、短肽、多种益生菌为主要原料,以氨基酸、益生元、碳水化合物、多种维生素及矿物质辅料,来源满足肌肉衰减综合征患者的营养需求,并补中益气,升阳举陷,滋补肝肾,开窍醒神、强壮筋骨、祛风通络、濡养生肌及增强人体免疫力。但是,长时间喝中药对胃肠功能会造成影响,而且有的人的肠胃并不适合喝中药,可能会导致恶心、呕吐等症状;且该全营养配方食品只补充了基本营养,未针对肌肉衰减综合症患者的症状给予特殊营养的补充。
因此,研制既能够满足肌肉衰减综合症患者全面均衡的营养需求,又能够改善肌肉衰减综合症患者的身体质量,促进肌力恢复和肌肉再生,并有助于缓解肌肉衰减综合症的其他症状的专用型临床营养配方显得尤为重要。
发明内容
本发明的目的在于克服现有技术中的缺陷,提供一种肌肉衰减综合症专用型临床营养配方及其制备方法,既能够满足肌肉衰减综合症患者全面均衡的营养需求,又能够改善肌肉衰减综合症患者的身体质量,促进肌力恢复和肌肉再生,促进骨骼肌蛋白合成,调节骨骼肌线粒体功能紊乱,并有助于缓解肌肉衰减综合症的其他症状。
为实现上述目的,本发明采用如下技术方案:
本发明的第一个目的是提供一种肌肉衰减综合症专用型临床营养配方,包括如下组分及其重量份数:18-30份蛋白质、9-13份脂肪、40-52份碳水化合物、4-8份膳食纤维、0.6-1.2份常量元素、0.01-0.03份微量元素、0.005-0.02份脂溶性维生素、0.005-0.20份水溶性维生素、0.2-1份膳***华、0.07-4份药食同源成分、0.1-1份天然植物化合物以及0.03-0.6份新资源食品;
其中,所述新资源食品包括初乳碱性蛋白、γ-氨基丁酸、壳寡糖、杜仲雄花、竹叶黄酮、酪蛋白磷酸肽、β-羟基-β-甲基丁酸钙、燕麦β-葡聚糖、酵母β-葡聚糖、乳矿物盐、玛咖粉、刺梨、低聚木糖中的至少一种;
其中,所述营养配方中,蛋白质:脂肪:碳水化合物的产能比为20~25:20~25:50~60。
为了进一步优化上述技术方案,本发明所采取的技术措施还包括:
进一步地,所述营养配方中,蛋白质:脂肪:碳水化合物的产能比为20~22:20~23:50~55;更进一步地,所述营养配方中,蛋白质:脂肪:碳水化合物的产能比为22:23:55。
进一步地,所述蛋白质包括水解乳清蛋白粉、大豆分离蛋白、鱼胶原蛋白、全脂奶粉、全蛋粉、乳铁蛋白、牛初乳、氨基酸、蛋白肽中的至少一种;其中,所述氨基酸包括L-赖氨酸-L-谷氨酸、L-谷氨酸、L-精氨酸、L-色氨酸、L-谷氨酰胺、牛磺酸、L-缬氨酸、L-异亮氨酸、L-亮氨酸中的至少一种;所述蛋白肽包括大豆低聚肽、小麦蛋白肽、蚕蛹蛋白肽、海洋鱼低聚肽粉、可乐肽、氨基肽、卵白蛋白肽中的至少一种。
进一步地,所述蛋白质包括15-20份的水解乳清蛋白;更进一步地,所述蛋白质包括18-19份的水解乳清蛋白。
进一步地,所述氨基酸包括4-8份的支链氨基酸;更进一步地,所述氨基酸包括5-6份的支链氨基酸。
更进一步地,所述支链氨基酸中亮氨酸的重量份数为2-4份;更进一步地,所述支链氨基酸中亮氨酸的重量份数为2-3份。
进一步地,所述脂肪包括饱和脂肪酸、多不饱和脂肪酸、单不饱和脂肪酸、OPO结构脂、DHA、EPA、ARA、磷脂中的至少一种。
进一步地,所述碳水化合物包括果糖、冰糖、乳糖、麦芽糊精、木薯淀粉、抗性淀粉中的至少两种;更进一步地,所述碳水化合物包括麦芽糊精和抗性淀粉。
进一步地,所述膳食纤维包括菊粉、魔芋粉、低聚半乳糖、低聚果糖、低聚异麦芽糖、大豆多糖、环糊精、抗性糊精、大豆纤维中的至少一种。
进一步地,所述膳食纤维中水溶性膳食纤维和不溶性膳食纤维的重量比例为5~8:0.8~1.5。
进一步地,所述常量元素包括柠檬酸钙、L-乳酸钙、磷酸氢钙、碳酸钙、葡萄糖酸钾、氯化钾、氯化钠、柠檬酸钠、葡萄糖酸镁、碳酸镁中的至少一种。
进一步地,所述微量元素包括葡萄糖酸亚铁、碘化钾、葡萄糖酸锌、***钠、葡萄糖酸铜、硫酸铜、硫酸铬、氯化铬、硫酸锰、葡萄糖酸锰和钼酸钠中的至少一种。
进一步地,所述脂溶性维生素包括维生素A、β-胡萝卜素、维生素D、维生素E、维生素K1中的至少一种;更进一步地,所述脂溶性维生素包括维生素D3、维生素A、维生素E、β-胡萝卜素;更进一步地,所述脂溶性维生素中维生素D的重量份数为0.000001-0.000005份;更进一步地,所述维生素D的重量份数为0.000001-0.000003份。
进一步地,所述水溶性维生素包括维生素B1、维生素B2、维生素B6、维生素B12、维生素C、泛酸、叶酸、烟酸、胆碱、肌醇、生物素中的至少一种。
进一步地,所述膳***华包括谷类、豆类、薯类、蔬菜类、菌藻类、坚果种子类、鱼虾类、禽畜肉类、水果类中的至少一种;其中,所述谷类包括大米粉、小米粉、黑米粉、薏米粉、玉米粉、小麦胚芽粉、燕麦粉、荞麦粉中的至少一种,所述豆类包括豌豆粉、绿豆粉、黑豆粉、红豆粉、大豆粉中的至少一种,所述薯类主要由淮山粉组成,所述蔬菜粉包括胡萝卜粉、白萝卜粉、南瓜粉、菠菜粉、番茄粉、西兰花粉、苦瓜粉中的至少一种,所述菌藻类包括香菇粉、海带粉、银耳粉中的至少一种,所述坚果种子类主要由南瓜子粉和莲子粉组成,所述鱼虾类包括三文鱼粉和鳕鱼粉中的至少一种,所述禽畜肉类包括鸡肉粉、牛肉粉和猪肾粉中的至少一种,所述水果类包括红枣粉、桂圆粉、苹果粉、樱桃粉、柑橘粉、雪梨粉中的至少一种。
进一步地,所述药食同源成分的重量份数为0.07-0.35份。
进一步地,所述药食同源成分包括淡豆豉、茯苓、覆盆子、百合、枸杞、黄精、薄荷、鸡内金、槐米、甘草中的至少一种;更进一步地,所述药食同源成分包括百合、枸杞、黄精、薄荷、鸡内金、槐米、甘草;更进一步地,所述药食同源成分中各组分的重量份数为:百合0.01-0.5份、枸杞0.01-0.5份、黄精0.01-0.5份、薄荷0.01-0.5份、鸡内金0.01-0.5份、槐米0.01-0.5份、甘草0.01-0.5份;更进一步地,所述药食同源成分中各组分的重量份数为:百合0.01-0.35份、枸杞0.01-0.35份、黄精0.01-0.35份、薄荷0.01-0.35份、鸡内金0.01-0.35份、槐米0.01-0.35份、甘草0.01-0.35份;
进一步地,所述天然植物化合物包括左旋肉碱、氨基葡萄糖、低聚果糖、叶黄素、植物甾醇、番茄红素、白藜芦醇、大蒜素中的至少一种;更进一步地,所述天然植物化合物为左旋肉碱,所述左旋肉碱的重量份数为0.5-1份。
进一步地,所述新资源食品的重量份数为0.03-0.21份。
进一步地,所述新资源食品包括乳矿物盐、燕麦β-葡聚糖、β-羟基-β-甲基丁酸钙。
进一步地,所述新资源食品中各组分的重量份数为:乳矿物盐0.01-0.5份、燕麦β-葡聚糖0.01-0.5份、β-羟基-β-甲基丁酸钙0.01-0.5份;更进一步地,所述新资源食品中各组分的重量份数为:乳矿物盐0.01-0.1份、燕麦β-葡聚糖0.01-0.1份、β-羟基-β-甲基丁酸钙0.01-0.1份。
本发明的第二个目的是提供一种上述肌肉衰减综合症专用型临床营养配方的制备方法,包括如下步骤:
步骤1,制备脂肪粉末;
步骤2,制备药食同源成分粉末:采用粉碎机对预定重量份数的原料进行粉碎,将粉碎的原料置于容器中,加入重量为原料重量的3~8倍的水,进行浸泡3~4小时,然后对浸泡液进行煎煮30~60min,过滤去除原料,留取煎煮液,对煎煮液进行喷雾干燥,以60~80目筛分制备药食同源成分粉末;
步骤3,制备脂溶性维生素粉末和水溶性维生素粉末:将预定重量份数的脂溶性维生素作为芯材,选用卡拉胶、***胶作为壁材,在高压下进行2次乳化均质处理,乳化均质时间为10~15min,然后进行喷雾瞬时干燥,以60~80目筛分制备脂溶性维生素粉末;将预定重量份数的水溶性维生素作为芯材,选用麦芽糊精、脂蛋白作为壁材,混合均匀,喷雾瞬时干燥,以60~80目筛分制备水溶性维生素粉末;
步骤4,将预定重量的蛋白质和氨基酸、碳水化合物、膳食纤维、微量元素、膳***华、天然植物化合物以及新资源食品分别制备成粒径为150~250μm的粉末;
步骤5,将步骤1~4所制得的粉末依次加入混合机混合均匀制得配方混合物,经过杀菌处理后备用;
步骤6,将所述配方混合物制备成营养粉、营养乳剂、胶囊剂、片剂、丸剂或口服液中的至少一种;
其中,步骤1~4的顺序可相互更换。
进一步地,所述步骤1中制备脂肪粉末具体包括如下步骤:
1)制备壁材水溶液:取麦芽糊精8g、大豆分离蛋白4g、全脂乳粉11g、膳食纤维2g、菊粉1.5g、水解乳清蛋白粉5g、低聚异麦芽糖0.5g、***胶0.2g、玉米淀粉0.5g、木薯淀粉2g、水50mL搅拌均匀;
2)将单甘酯取0.1g(总固形物浓度为0.2%)均匀溶于10.3mL混合植物油脂中;所述混合植物油脂由0.6mL紫苏油、2.6mL椰子油、4.2mL大豆油、2.6mL橄榄油、0.3mL中链甘油三酯组成;
3)将吐温80取0.1g(总固形物浓度为0.2%)均匀溶于所述壁材水溶液中;
4)将添加过乳化剂单甘酯的混合植物油脂与添加过乳化剂吐温80的壁材水溶液充分混合,得到混合溶液;
5)添加稳定剂琼脂0.1g(总固形物浓度为0.2%)于所述混合溶液后,用水定容至200mL(总固形物浓度为25%),20000r/min下高速分散2分钟,得到乳状液;
6)将所述乳状液在均质压力25MPa下,均质3次,每次5分钟,得到均质乳状液;
7)将所述均质乳状液进行喷雾干燥,进风温度为195℃,出风温度为80℃,收集得到脂肪粉末。
进一步地,所述步骤6中可选择性地增加适量的食品增稠剂和食品添加剂。其中,所述食品增稠剂包括瓜尔胶、黄原胶、槐豆胶、魔芋胶、果胶、卡拉胶、琼脂、明胶、***胶中的至少一种,所述食品添加剂包括阿斯巴甜、食用香精香料、红糖中的至少一种。更优选为卡拉胶、***胶、瓜尔胶、阿斯巴甜、食用香精香料。
进一步地,上述肌肉衰减征专用型临床营养配方的制备方法的操作步骤均需在惰性气体的保护下进行,所使用的惰性气体为氮气、氩气、氦气等。在惰性气体的保护下进行上述操作步骤可以防止产生粉末***的危险。
本发明中采用包括百合、薄荷、甘草、枸杞、黄精、槐米、鸡内金的药食同源成分,上述成分配伍增效后具有提高免疫力、促进机体营养代谢、缓解肌肉痉挛、减少肌肉有关的氧化应激损伤、降低血压的功效。
百合中的蛋白质、氨基酸和多糖可提高人体的免疫力,还含有多种营养物质,如矿物质、维生素等,这些物质能促进机体营养代谢,使机体抗疲劳、耐缺氧能力增强,同时能清除体内的有害物质,延缓衰老;
薄荷味辛,性凉;归肺、肝经;清香升散;具有疏风散热,清头目,利咽喉,透疹,解郁的功效,另外薄荷还具有消炎止痛的作用,可缓解肌肉痉挛;
甘草含有多种化学成分,主要为甘草酸、甘草甙,甘草酸具有较强的增加人体免疫功能作用,甘草甙具有抗氧化功能;
枸杞营养丰富,富含枸杞多糖,枸杞多糖是一种水溶性多糖,由***糖、葡萄糖、半乳糖、甘露糖、木糖、鼠李糖这6种单糖成分组成,具有生理活性,能够增强非特异性免疫功能,提高抗病能力,抑制肿瘤生长和细胞突变;含有β-胡萝卜素、微量元素硒和维生素E,具有强大的抗氧化功能,有助于减少肌肉有关的氧化应激损伤;
黄精滋肾润肺,补脾益气,强筋骨,具有抗氧化、延缓衰老的功能;其抗氧化功效有助于减少肌肉有关的氧化应激损伤,其延缓衰老功效有助于提高老人身体质量;
槐米富含蛋白质,槐花所含的芸香甙(芦丁)是具有增强毛细血管抵抗力的维生素,可增强血管壁弹性,提高毛细血管的韧性,具有降低血压的功能;肌肉衰减综合症可造成人体基础代谢率降低,进而引起2型糖尿病、肥胖、血脂异常和高血压等并发症,肌肉衰减综合症患者补充槐米有助于避免高血压的发生;
鸡内金能够促进肠胃消化功能,具有较强的消食化积作用,并能健运脾胃,能够促进患者对本发明的临床营养配方中的其他营养组分的吸收。
本发明中采用包括乳矿物盐、燕麦β-葡聚糖、β-羟基-β-甲基丁酸钙的新资源食品,上述成分配伍增效后具有增强骨密度、提高免疫能力、促进营养吸收、促进蛋白质合成、减轻慢性感染,促进肌肉再生的功效。
乳矿物盐具有增强骨密度的作用,老年人在发生肌肉衰减综合症之外还会发生其他并发症如骨质疏松症状,乳矿物盐有助于缓解肌肉衰减综合症的并发症的发生;研究表明,乳矿物盐与其他钙源(如醋酸钙等)相比,不仅可以获得骨密度的增加,而且在补充乳钙几年后,骨密度仍然持续增长,但补充无机钙的骨密度在停止补钙后骨密度增加会发生逆转;因此,骨质疏松症状的患者补充乳矿物盐尤为重要;
燕麦β-葡聚糖具有显著的降血脂、降血糖及提高免疫能力,维持肠道微生态环境等功能,它还能加快确定人群的免疫细胞,对细菌感染的反应并控制住细菌感染的位置,使感染尽快恢复,而且燕麦β-葡聚糖在小肠中不能水解,而在大肠中降解并作为细菌发酵的底物,发酵产生短链脂肪酸,特别是丁酸,有益于肠道功能,.燕麦β一葡聚糖能使小鼠肠道和粪便中双歧杆菌和乳酸杆菌增值,而使大肠杆菌的数量减少,因此燕麦葡聚糖还具有改善肠道功能,促进肠道有益菌的增值,因此,添加了燕麦β-葡聚糖的本发明的临床营养配方,患者服用后能够促进其他营养组分的吸收;
β-羟基-β-甲基丁酸(CaHMB)是一种被广泛用于健身者或者运动员的亮氨酸代谢产物,对于肌少症具有预防与治疗作用;HMB是胆固醇合成的前体物,在保护细胞膜结构、维持骨骼肌细胞完整等方面发挥重要的作用,可以促进蛋白质的合成,减少蛋白质的降解,减轻慢性感染,促进肌肉再生,其机理是通过上调蛋白质合成信号通路以及下调蛋白分解信号通路两方面来促进蛋白质合成减缓肌肉分解。
本发明采用上述技术方案,与现有技术相比,具有如下技术效果:
1)本发明的肌肉衰减综合症专用型临床营养配方采用20~25:20~25:50~60的蛋白质:脂肪:碳水化合物的供能比例,为患者提供均衡的营养补充。
2)添加水解乳清蛋白15-20份,根据不同蛋白质的可消化性和生物利用度不同,可将蛋白质分为“快蛋白”和“慢蛋白”,“快蛋白”的特点是在消化后能较快地以氨基酸的形式出现在血液中,“慢蛋白”的特点是餐后血浆中的氨基酸升高速度较慢,乳清蛋白即为典型的快蛋白;由于血浆中氨基酸升高的程度和时间是解决肌肉衰减综合症人群的肌肉对氨基酸敏感性降低的重要因素,因此,“快蛋白”对于患有肌肉衰减综合症的老年人群有着十分重要的意义。
3)添加支链氨基酸4-8份,支链氨基酸包括亮氨酸、异亮氨酸、缬氨酸,作为氮的载体,辅助合成所需的其它氨基酸;支链氨基酸能够刺激胰岛素的产生,胰岛素的主要作用就是允许外周血糖被肌肉吸收并作为能量来源,同时在促进肌肉生长方面它还具有和生长激素协同的效应,更好的促进肌肉生长;添加上述重量份数的支链氨基酸于本发明的临床营养配方中,能够加快肌肉衰减综合症患者的肌肉恢复。
4)支链氨基酸中亮氨酸的重量份数为2-4份,有研究显示,亮氨酸强化的氨基酸混合物可以提升老年人蛋白质净合成水平,相比之下,对年轻人增加亮氨酸摄入量并不会增强肌肉蛋白质合成;初步研究机理显示,亮氨酸可通过激活哺乳动物霉帕霉素靶蛋白mTOR及真核启动因子途径和作为胰岛素促分泌素这两种方式来刺激蛋白合成;添加适量氨基酸可以发挥亮氨酸在合成蛋白以外的功能,即作为信号刺激蛋白的合成;添加上述重量份数的亮氨酸于本发明的临床营养配方中,能够加快肌肉衰减综合症患者的蛋白质的合成,从而能最大限度地刺激患者肌肉蛋白质的合成,增加并保持肌肉质量。
5)添加维生素D,维生素D受体(VDR)广泛分布于人体的各个组织,1,25(OH)2D通过与VDR结合发挥生物效应,从而引起肌肉蛋白质的合成、骨骼肌纤维的增殖分化以及骨骼肌Ⅱ型肌纤维体积的增大和数量的增加;此外,维生素D可与膜受体结合,激活可诱导磷脂酶C和MAP激酶的信号转导通路,使大量钙离子进入细胞从而影响肌肉的收缩功能,添加上述重量份数的维生素D于本发明的临床营养配方中,能够有效防治肌少症的发生和发展,且可显著改善肌力和肌肉的功能。
本发明通过选用合理配比的基础营养素,同时添加具有提高免疫能力、增强骨密、促进营养吸收、减轻慢性感染、促进肌肉再生、缓解肌肉痉挛、减少肌肉有关的氧化应激损伤的功效的膳食纤维、膳***华、药食同源成分、天然植物化合物、新资源食品等特殊营养物质,既能够满足肌肉衰减综合症患者全面均衡的营养需求,又能够改善肌肉衰减综合症患者的身体质量,促进肌力恢复和肌肉再生,促进骨骼肌蛋白合成,调节骨骼肌线粒体功能紊乱及体液因子和细胞因子改变,并有助于缓解肌肉衰减综合症的其他症状。
具体实施方式
本发明提供了一种肌肉衰减综合症专用型临床营养配方,其特征在于,包括如下组分及其重量份数:18-30份蛋白质、9-13份脂肪、40-52份碳水化合物、4-8份膳食纤维、0.6-1.2份常量元素、0.01-0.03份微量元素、0.005-0.02份脂溶性维生素、0.005-0.20份水溶性维生素、0.2-1份膳***华、0.07-4份药食同源成分、0.1-1份天然植物化合物以及0.03-0.6份新资源食品;其中,所述新资源食品包括初乳碱性蛋白、γ-氨基丁酸、壳寡糖、杜仲雄花、竹叶黄酮、酪蛋白磷酸肽、β-羟基-β-甲基丁酸钙、燕麦β-葡聚糖、酵母β-葡聚糖、乳矿物盐、玛咖粉、刺梨、低聚木糖中的至少一种;其中,所述营养配方中,蛋白质:脂肪:碳水化合物的产能比为20~25:20~25:50~60。
下面通过具体实施例对本发明进行详细和具体的介绍,以使更好的理解本发明,但是下述实施例并不限制本发明范围。
实施例1
本发明所述的肌肉衰减综合症专用型临床营养配方包括水解乳清蛋白粉18.1g、支链氨基酸5.45g、全脂奶粉4.54g、全蛋粉0.18g、牛初乳冻干粉0.18g、牛磺酸0.12g;海洋鱼低聚肽粉0.09g、紫苏油0.55g、椰子油2.36g、大豆油3.82g、橄榄油2.36g、中链甘油三酯0.29g;麦芽糊精32.16g、抗性淀粉12.73g;水溶性膳食纤维6.18g、不溶性膳食纤维0.9g;钙0.2g、磷0.21g、钾0.08g、钠0.02g、镁0.15g;铁0.011g、碘0.00014g、锌0.007g;维生素A0.0006g、β-胡萝卜素0.000057g、维生素D3 0.000003g、维生素E 0.009g;维生素B1 0.001g、维生素B2 0.001g、维生素B6 0.001g、维生素B12 0.000002g、维生素C 0.15g、泛酸0.003g、叶酸0.000165g、烟酸0.0165g;膳***华1g;百合0.05g、薄荷0.05g、甘草0.05g、枸杞0.05g、黄精0.05g、槐米0.05g、鸡内金0.05g;左旋肉碱0.64g;乳矿物盐0.09g、燕麦β-葡聚糖0.02g、β-羟基-β-甲基丁酸钙0.1g;
其中,所述支链氨基酸中亮氨酸3g。
实施例2
本发明所述的肌肉衰减综合症专用型临床营养配方包括水解乳清蛋白粉18.1g、支链氨基酸5.45g、全脂奶粉4.54g、全蛋粉0.18g、牛初乳冻干粉0.18g、牛磺酸0.12g;海洋鱼低聚肽粉0.09g、紫苏油0.55g、椰子油2.36g、大豆油3.82g、橄榄油2.36g、中链甘油三酯0.29g;麦芽糊精32.16g、抗性淀粉12.73g;水溶性膳食纤维6.18g、不溶性膳食纤维0.9g;钙0.2g、磷0.21g、钾0.08g、钠0.02g、镁0.15g;铁0.011g、碘0.00014g、锌0.007g;维生素A0.0006g、β-胡萝卜素0.000057g、维生素D3 0.000003g、维生素E 0.009g;维生素B1 0.001g、维生素B2 0.001g、维生素B6 0.001g、维生素B12 0.000002g、维生素C0.15g、泛酸0.003g、叶酸0.000165g、烟酸0.0165g;膳***华1g;百合0.05g、薄荷0.05g、甘草0.05g、枸杞0.05g、黄精0.05g、槐米0.05g、鸡内金0.05g;左旋肉碱0.64g;酪蛋白磷酸肽0.09g、γ-氨基丁酸0.02g、β-羟基-β-甲基丁酸钙0.1g;
其中,所述支链氨基酸中亮氨酸3g。
实施例3
本发明所述的肌肉衰减综合症专用型临床营养配方包括水解乳清蛋白粉18.1g、支链氨基酸5.45g、全脂奶粉4.54g、全蛋粉0.18g、牛初乳冻干粉0.18g、牛磺酸0.01g、海洋鱼低聚肽粉0.09g;紫苏油0.55g、椰子油2.36g、大豆油3.82g、橄榄油2.36g、中链甘油三酯0.29g;麦芽糊精32.16g、抗性淀粉12.73g;水溶性膳食纤维6.18g、不溶性膳食纤维0.9g;钙0.2g、磷0.21g、钾0.08g、钠0.02g、镁0.15g;铁0.011g、碘0.00014g、锌0.007g;维生素A0.0006g、β-胡萝卜素0.000057g、维生素D3 0.000003g、维生素E 0.009g;维生素B1 0.001g、维生素B2 0.001g、维生素B6 0.001g、维生素B12 0.000002g、维生素C 0.15g、泛酸0.003g、叶酸0.000165g、烟酸0.0165g;膳***华1g;百合0.05g、薄荷0.05g、甘草0.05g、枸杞0.05g、黄精0.05g、槐米0.05g、鸡内金0.05g;左旋肉碱0.64g;乳矿物盐0.09g、燕麦β-葡聚糖0.02g、β-羟基-β-甲基丁酸钙0.1g;
其中,所述支链氨基酸中亮氨酸2g。
实施例4
本发明所述的肌肉衰减综合症专用型临床营养配方包括水解乳清蛋白粉18.1g、支链氨基酸5.45g、全脂奶粉4.54g、全蛋粉0.18g、牛初乳冻干粉0.18g、牛磺酸0.12g、海洋鱼低聚肽粉0.01g;紫苏油0.55g、椰子油2.36g、大豆油3.82g、橄榄油2.36g、中链甘油三酯0.29g;麦芽糊精32.16g、抗性淀粉12.73g;水溶性膳食纤维6.18g、不溶性膳食纤维0.9g;钙0.2g、磷0.21g、钾0.08g、钠0.02g、镁0.15g;铁0.011g、碘0.00014g、锌0.007g;维生素A0.0006g、β-胡萝卜素0.000057g、维生素D3 0.000003g、维生素E 0.009g;维生素B1 0.001g、维生素B2 0.001g、维生素B6 0.001g、维生素B12 0.000002g、维生素C0.15g、泛酸0.003g、叶酸0.000165g、烟酸0.0165g;膳***华1g;百合0.01g、薄荷0.01g、甘草0.01g、枸杞0.01g、黄精0.01g、槐米0.01g、鸡内金0.01g;左旋肉碱0.64g;乳矿物盐0.09g、燕麦β-葡聚糖0.02g、β-羟基-β-甲基丁酸钙0.1g;
其中,所述支链氨基酸中亮氨酸2g。
实施例5
本发明所述的肌肉衰减综合症专用型临床营养配方包括水解乳清蛋白粉18.1g、支链氨基酸5.45g、全脂奶粉4.54g、全蛋粉0.18g、牛初乳冻干粉0.18g、牛磺酸0.12g、海洋鱼低聚肽粉0.09g;紫苏油0.55g、椰子油2.36g、大豆油3.82g、橄榄油2.36g、中链甘油三酯0.29g;麦芽糊精32.16g、抗性淀粉12.73g;水溶性膳食纤维6.18g、不溶性膳食纤维0.9g;钙0.2g、磷0.21g、钾0.08g、钠0.02g、镁0.15g;铁0.011g、碘0.00014g、锌0.007g;维生素A0.0006g、β-胡萝卜素0.000057g、维生素D3 0.000001g、维生素E 0.009g;维生素B1 0.001g、维生素B2 0.001g、维生素B6 0.001g、维生素B12 0.000002g、维生素C0.15g、泛酸0.003g、叶酸0.000165g、烟酸0.0165g;膳***华1g;百合0.01g、薄荷0.01g、甘草0.01g、枸杞0.01g、黄精0.01g、槐米0.01g、鸡内金0.01g;左旋肉碱0.64g;乳矿物盐0.01g、燕麦β-葡聚糖0.01g、β-羟基-β-甲基丁酸钙0.01g;
其中,所述支链氨基酸中亮氨酸4g。
实施例6
一种如实施例1~实施例5所述的肌肉衰减综合症专用型临床营养配方的制备方法如下:
1)制备粉末油脂(粉末脂肪):
a)制备壁材水溶液:取麦芽糊精8g、大豆分离蛋白4g、全脂乳粉11g、膳食纤维2g(抗性糊精)、菊粉1.5g、水解乳清蛋白粉5g、低聚异麦芽糖0.5g、***胶0.2g、玉米淀粉0.5g、木薯淀粉粉2g、水50mL搅拌均匀(有条件边加热边搅拌至60℃,保持30分钟后冷却至室温)。
b)将单甘酯取0.1g(总固形物浓度为0.2%)均匀溶于10.3mL混合植物油脂中;混合植物油脂由0.6mL紫苏油、2.6mL椰子油、4.2mL大豆油、2.6mL橄榄油、0.3mL中链甘油三酯组成。
c)将吐温80取0.1g(总固形物浓度为0.2%)均匀溶于壁材水溶液中。
d)将添加过乳化剂单甘酯的混合植物油脂与添加过乳化剂吐温80的壁材水溶液充分混合。
e)添加稳定剂琼脂取0.1g(总固形物浓度为0.2%)进混合溶液后,用水定容至200毫升(总固形物浓度为25%),20000r/min下高速分散2分钟。
f)均质压力为25MPa,均质3次(每次5分钟),制得均质乳状液。
g)将制得的乳状液进行喷雾干燥,进风温度为195℃,出风温度为80℃。收集粉末油脂(粉末脂肪)。
2)制备药食同源成分粉末:采用粉碎机对预定重量份数的原料进行粉碎,将粉碎的原料置于容器中,加入重量为原料重量的3~8倍的水,进行浸泡3~4小时,然后对浸泡液进行煎煮30~60min,过滤去除原料,留取煎煮液,对煎煮液进行喷雾干燥,以60~80目筛分制备药食同源成分粉末;
3)制备维生素粉末:将预定重量份数的脂溶性维生素作为芯材,选用卡拉胶、***胶作为壁材,在高压下进行2次乳化均质处理,乳化均质时间为10~15min,然后进行喷雾瞬时干燥,以60~80目筛分制备脂溶性维生素粉末;将预定重量份数的水溶性维生素作为芯材,选用麦芽糊精、脂蛋白作为壁材,混合均匀,喷雾瞬时干燥,以60~80目筛分制备水溶性维生素粉末;
4)将预定重量的蛋白质和氨基酸、核苷酸、碳水化合物、膳食纤维、常量元素、微量元素、膳***华、天然植物化合物以及新资源食品分别制备成粒径为150~250μm的粉末;
5)将步骤1)~步骤4)所制得的粉末依次加入锥形混合机或其他形式的混合机混合均匀制得配方混合物,经过杀菌处理后,备用;
6)根据常规技术手段将步骤5)中的配方混合物制备成营养粉、营养乳剂、胶囊剂、片剂、丸剂或口服液中的至少一种。
在步骤6)中,可选择性地增加适量的食品增稠剂和食品添加剂。所述食品增稠剂为瓜尔胶、黄原胶、槐豆胶、魔芋胶、果胶、卡拉胶、琼脂、明胶、***胶中的至少一种,所述食品添加剂为阿斯巴甜、食用香精香料、红糖中的至少一种;更优选卡拉胶、***胶、瓜尔胶、阿斯巴甜、食用香精香料。
上述操作步骤均需在惰性气体的保护下进行,比如氮气、氩气、氦气等,以防止产生粉末***的危险。
按照所述配方可制备成粉状、颗粒状、胶囊状、片剂状、饮料等类别。
实施例7
本实施例为验证实施例。
本验证实施例验证本发明所述的肌肉衰减综合症专用型临床营养配方对肌肉衰减患者的影响。本实施例采用实施例1和2的配方制备的营养粉以及下述对比例:
对照组:采用常规营养粉;
实验组1:采用实施例1的营养配方制备的营养粉;
实验组2:采用实施例2的营养配方制备的营养粉;
实验组3:采用实施例1的营养配方中删除药食同源成分制备的营养粉;
实验组4:采用实施例1的营养配方中删除新资源食品制备的营养粉;
实验组5:采用实施例1的营养配方中删除支链氨基酸制备的营养粉;
以上每组选用自愿服用相应营养粉的肌肉衰减患者20名,所选患者的年龄分布为50-60岁,男女比例1:1;在维持正常抗阻训练和有氧运动训练期间给予上述营养粉食用;每日早晚一次,冲服,2个月后进行实验结果统计。
实验结果均为平均值,实验结果如下表所示:
表一为食用前后患者肌肉力量指标的变化比较:
握力采用汇海电子握力计测量,测试过程中,受试者用力时不准曲臂、挥臂、弯腰或持握力计的手家畜身体其他部位;
背力和腿肌力采用江苏南通衡器厂BCS-400电子背力计测量,测试过程中,上拉背力计时屈体、屈臂或身体后倒。
表一 食用前后患者肌肉力量指标的变化(kg)
表二为食用后患者肌肉质量指标的测量结果:
测试方法为采用肌肉质量测试四法进行测量(上梯耐力测试法、上梯耐力测试法、肌耐力测试法和起坐肌力测试法),评价标准如下:
0:上梯后感觉轻松;30秒钟内能够完成30次以上仰卧坐起;指尖能够向前伸过脚尖;30秒钟内能够完成30次以上站起坐下;
1:上梯后感觉较轻松;30秒钟内能够完成20-30次仰卧坐起;指尖能够向前碰到脚尖;30秒钟内能够完成20-30次站起坐下;
2:上梯后感觉较吃力;30秒钟内能够完成10-20次仰卧坐起;指尖能够向前接近但不能碰到脚尖;30秒钟内能够完成10-20次站起坐下;
3:上梯后感觉吃力;30秒钟内能够完成0-10次仰卧坐起;指尖向前后离脚尖有较长一段距离;30秒钟内能够完成0-10次站起坐下。
表二 食用后患者肌肉质量指标的测量结果(n(%))
从上表可知,本发明所述的肌肉衰减综合症专用型临床营养配方能够明显改善患者的肌肉力量和肌肉质量。未添加本发明的药食同源成分、新资源食品或支链氨基酸的临床营养配方其效果高于采用常规营养粉的对照组,但略低于添加了本发明的药食同源成分、新资源食品和支链氨基酸的临床营养配方的实验组。说明药食同源成分、新资源食品或支链氨基酸等组分对于改善肌肉衰减综合症效果的实现是必不可少的,其与本发明其他组分相辅相成,充分发挥各自的功效,才能取得优异的效果。
由上述实施例可知,本发明所述的肌肉衰减综合症专用型临床营养配方既能够满足肌肉衰减综合症患者全面均衡的营养需求,又能够改善肌肉衰减综合症患者的身体质量,促进肌力恢复和肌肉再生,促进骨骼肌蛋白合成,调节骨骼肌线粒体功能紊乱,并有助于缓解肌肉衰减综合症的其他症状;本发明采用的药食同源成分配伍增效后具有提高免疫力、促进机体营养代谢、缓解肌肉痉挛、减少肌肉有关的氧化应激损伤、降低血压的功效;本发明采用的新资源食品配伍增效后具有增强骨密度、提高免疫能力、促进营养吸收、促进蛋白质合成、减轻慢性感染,促进肌肉再生的功效。
以上对本发明的具体实施例进行了详细描述,但其只是作为范例,本发明并不限制于以上描述的具体实施例。对于本领域技术人员而言,任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此,在不脱离本发明的精神和范围下所作的均等变换和修改,都应涵盖在本发明的范围内。
Claims (9)
1.一种肌肉衰减综合症专用型临床营养配方,其特征在于,包括如下组分及其重量份数:18-30份蛋白质、9-13份脂肪、40-52份碳水化合物、4-8份膳食纤维、0.6-1.2份常量元素、0.01-0.03份微量元素、0.005-0.02份脂溶性维生素、0.005-0.20份水溶性维生素、0.2-1份膳***华、0.07-4份药食同源成分、0.1-1份天然植物化合物以及0.03-0.6份新资源食品;
其中,所述新资源食品包括初乳碱性蛋白、γ-氨基丁酸、壳寡糖、杜仲雄花、竹叶黄酮、酪蛋白磷酸肽、β-羟基-β-甲基丁酸钙、燕麦β-葡聚糖、酵母β-葡聚糖、乳矿物盐、玛咖粉、刺梨、低聚木糖中的至少一种;
其中,所述营养配方中,蛋白质:脂肪:碳水化合物的产能比为20~25:20~25:50~60。
2.根据权利要求1所述的肌肉衰减综合症专用型临床营养配方,其特征在于,所述蛋白质包括15-20份的水解乳清蛋白。
3.根据权利要求1所述的肌肉衰减综合症专用型临床营养配方,其特征在于,所述蛋白质包括氨基酸,所述氨基酸包括4-8份的支链氨基酸。
4.根据权利要求3所述的肌肉衰减综合症专用型临床营养配方,其特征在于,所述支链氨基酸中亮氨酸的重量份数为2-4份。
5.根据权利要求1所述的肌肉衰减综合症专用型临床营养配方,其特征在于,所述药食同源成分的重量份数为0.07-0.35份。
6.根据权利要求1所述的肌肉衰减综合症专用型临床营养配方,其特征在于,所述新资源食品包括乳矿物盐、燕麦β-葡聚糖、β-羟基-β-甲基丁酸钙。
7.根据权利要求1所述的肌肉衰减综合症专用型临床营养配方,其特征在于,所述新资源食品中各组分的重量份数为:乳矿物盐0.01-0.5份、燕麦β-葡聚糖0.01-0.5份、β-羟基-β-甲基丁酸钙0.01-0.5份。
8.根据权利要求1-7中任一项所述的肌肉衰减综合症专用型临床营养配方的制备方法,其特征在于,包括如下步骤:
步骤1,制备脂肪粉末;
步骤2,制备药食同源成分粉末:采用粉碎机对预定重量份数的原料进行粉碎,将粉碎的原料置于容器中,加入重量为原料重量的3~8倍的水,进行浸泡3~4小时,然后对浸泡液进行煎煮30~60min,过滤去除原料,留取煎煮液,对煎煮液进行喷雾干燥,以60~80目筛分制备药食同源成分粉末;
步骤3,制备脂溶性维生素粉末和水溶性维生素粉末:将预定重量份数的脂溶性维生素作为芯材,选用卡拉胶、***胶作为壁材,在高压下进行2次乳化均质处理,乳化均质时间为10~15min,然后进行喷雾瞬时干燥,以60~80目筛分制备脂溶性维生素粉末;将预定重量份数的水溶性维生素作为芯材,选用麦芽糊精、脂蛋白作为壁材,混合均匀,喷雾瞬时干燥,以60~80目筛分制备水溶性维生素粉末;
步骤4,将预定重量的蛋白质和氨基酸、碳水化合物、膳食纤维、微量元素、膳***华、天然植物化合物以及新资源食品分别制备成粒径为150~250μm的粉末;
步骤5,将步骤1~4所制得的粉末依次加入混合机混合均匀制得配方混合物,经过杀菌处理后备用;
步骤6,将所述配方混合物制备成营养粉、营养乳剂、胶囊剂、片剂、丸剂或口服液中的至少一种;
其中,步骤1~4的顺序可相互更换。
9.根据权利要求8所述的制备方法,其特征在于,所述步骤1中制备脂肪粉末具体包括如下步骤:
1)制备壁材水溶液:取麦芽糊精8g、大豆分离蛋白4g、全脂乳粉11g、膳食纤维2g、菊粉1.5g、水解乳清蛋白粉5g、低聚异麦芽糖0.5g、***胶0.2g、玉米淀粉0.5g、木薯淀粉2g、水50mL搅拌均匀;
2)将单甘酯取0.1g(总固形物浓度为0.2%)均匀溶于10.3mL混合植物油脂中;所述混合植物油脂由0.6mL紫苏油、2.6mL椰子油、4.2mL大豆油、2.6mL橄榄油、0.3mL中链甘油三酯组成;
3)将吐温80取0.1g(总固形物浓度为0.2%)均匀溶于所述壁材水溶液中;
4)将添加过乳化剂单甘酯的混合植物油脂与添加过乳化剂吐温80的壁材水溶液充分混合,得到混合溶液;
5)添加稳定剂琼脂0.1g(总固形物浓度为0.2%)于所述混合溶液后,用水定容至200mL(总固形物浓度为25%),20000r/min下高速分散2分钟,得到乳状液;
6)将所述乳状液在均质压力25MPa下,均质3次,每次5分钟,得到均质乳状液;
7)将所述均质乳状液进行喷雾干燥,进风温度为195℃,出风温度为80℃,收集得到脂肪粉末。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810444528.6A CN108618129A (zh) | 2018-05-10 | 2018-05-10 | 肌肉衰减综合症专用型临床营养配方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810444528.6A CN108618129A (zh) | 2018-05-10 | 2018-05-10 | 肌肉衰减综合症专用型临床营养配方及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108618129A true CN108618129A (zh) | 2018-10-09 |
Family
ID=63692638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810444528.6A Pending CN108618129A (zh) | 2018-05-10 | 2018-05-10 | 肌肉衰减综合症专用型临床营养配方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108618129A (zh) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109222103A (zh) * | 2018-11-29 | 2019-01-18 | 汤臣倍健股份有限公司 | 增肌组合物和保健食品 |
CN109349618A (zh) * | 2018-10-23 | 2019-02-19 | 上海奥医生物医药科技有限公司 | 便秘专用型临床营养配方及其制备方法 |
CN109430884A (zh) * | 2018-11-26 | 2019-03-08 | 荣海生物科技有限公司 | 小分子肽多种生物营养剂及其制备方法 |
CN109497514A (zh) * | 2018-10-23 | 2019-03-22 | 上海奥医生物医药科技有限公司 | 艾滋病专用型临床营养配方及其制备方法 |
CN109527585A (zh) * | 2018-12-26 | 2019-03-29 | 浙江华康药业股份有限公司 | 一种能预防和缓解肌少症的营养组合物及其制备方法 |
CN109846026A (zh) * | 2018-12-20 | 2019-06-07 | 广东永青生物科技有限公司 | 一组以结晶果糖为主要能源原料制备的果糖能量早茶 |
CN111035017A (zh) * | 2019-12-12 | 2020-04-21 | 山东省药学科学院 | 一种防治肌肉流失的口服液 |
CN111264821A (zh) * | 2020-02-21 | 2020-06-12 | 山东师范大学 | 一种有助于缓解肌肉衰减的组合物、果冻制品及制备方法 |
CN111972672A (zh) * | 2020-08-25 | 2020-11-24 | 黑龙江省完达山乳业股份有限公司 | 一种具有增加肌肉功能的组合物及其应用 |
CN112155057A (zh) * | 2020-08-25 | 2021-01-01 | 石家庄君乐宝乳业有限公司 | 高蛋白增肌稠厚型调制乳粉及其制备方法 |
CN113398144A (zh) * | 2021-07-27 | 2021-09-17 | 大连双迪科技股份有限公司 | 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用 |
CN114209066A (zh) * | 2021-12-08 | 2022-03-22 | 国珍健康科技(北京)有限公司 | 一种用于改善肌肉衰减的组合物及其制备方法和应用 |
CN114304287A (zh) * | 2022-01-06 | 2022-04-12 | 江南大学 | 肌肉衰减综合征医学配方食品中用的脂肪组件、制备方法及应用 |
CN114431380A (zh) * | 2022-02-25 | 2022-05-06 | 广东君悦营养医学有限公司 | 一种适用于肌肉衰减综合症的蛋白水及其制备方法 |
CN114680339A (zh) * | 2022-04-12 | 2022-07-01 | 天津医科大学 | 一种改善肌肉衰减延缓衰老的营养补充剂及其应用 |
CN115177000A (zh) * | 2021-04-07 | 2022-10-14 | 陕西罗麻丹医药有限公司 | 一种改善老年肌少症的粉剂及其制备方法 |
WO2022226828A1 (zh) * | 2021-04-28 | 2022-11-03 | 益达生医股份有限公司 | 供改善肌少症的营养组合物及其用途 |
CN116473236A (zh) * | 2023-04-19 | 2023-07-25 | 安徽昊天生物科技有限公司 | 一种运动后恢复型运动营养食品及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106666728A (zh) * | 2016-12-23 | 2017-05-17 | 上海奥医生物医药科技有限公司 | 一种妊娠糖尿病专用型临床营养配方及其制备方法 |
CN106858620A (zh) * | 2017-03-29 | 2017-06-20 | 上海奥医生物医药科技有限公司 | 一种贫血专用型临床营养配方及其制备方法 |
CN106962912A (zh) * | 2017-03-29 | 2017-07-21 | 上海奥医生物医药科技有限公司 | 一种肝病专用型临床营养配方及其制备方法 |
CN106983151A (zh) * | 2017-03-29 | 2017-07-28 | 上海奥医生物医药科技有限公司 | 一种炎性肠病专用型临床营养配方及其制备方法 |
CN107440103A (zh) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | 一种呼吸***疾病专用型临床营养配方及其制备方法 |
CN107616490A (zh) * | 2017-08-23 | 2018-01-23 | 上海奥医生物医药科技有限公司 | 一种儿童术后专用型临床营养配方及其制备方法 |
-
2018
- 2018-05-10 CN CN201810444528.6A patent/CN108618129A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106666728A (zh) * | 2016-12-23 | 2017-05-17 | 上海奥医生物医药科技有限公司 | 一种妊娠糖尿病专用型临床营养配方及其制备方法 |
CN106858620A (zh) * | 2017-03-29 | 2017-06-20 | 上海奥医生物医药科技有限公司 | 一种贫血专用型临床营养配方及其制备方法 |
CN106962912A (zh) * | 2017-03-29 | 2017-07-21 | 上海奥医生物医药科技有限公司 | 一种肝病专用型临床营养配方及其制备方法 |
CN106983151A (zh) * | 2017-03-29 | 2017-07-28 | 上海奥医生物医药科技有限公司 | 一种炎性肠病专用型临床营养配方及其制备方法 |
CN107440103A (zh) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | 一种呼吸***疾病专用型临床营养配方及其制备方法 |
CN107616490A (zh) * | 2017-08-23 | 2018-01-23 | 上海奥医生物医药科技有限公司 | 一种儿童术后专用型临床营养配方及其制备方法 |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109349618A (zh) * | 2018-10-23 | 2019-02-19 | 上海奥医生物医药科技有限公司 | 便秘专用型临床营养配方及其制备方法 |
CN109497514A (zh) * | 2018-10-23 | 2019-03-22 | 上海奥医生物医药科技有限公司 | 艾滋病专用型临床营养配方及其制备方法 |
CN109430884A (zh) * | 2018-11-26 | 2019-03-08 | 荣海生物科技有限公司 | 小分子肽多种生物营养剂及其制备方法 |
CN109222103A (zh) * | 2018-11-29 | 2019-01-18 | 汤臣倍健股份有限公司 | 增肌组合物和保健食品 |
CN109846026A (zh) * | 2018-12-20 | 2019-06-07 | 广东永青生物科技有限公司 | 一组以结晶果糖为主要能源原料制备的果糖能量早茶 |
CN109527585A (zh) * | 2018-12-26 | 2019-03-29 | 浙江华康药业股份有限公司 | 一种能预防和缓解肌少症的营养组合物及其制备方法 |
CN111035017A (zh) * | 2019-12-12 | 2020-04-21 | 山东省药学科学院 | 一种防治肌肉流失的口服液 |
CN111264821A (zh) * | 2020-02-21 | 2020-06-12 | 山东师范大学 | 一种有助于缓解肌肉衰减的组合物、果冻制品及制备方法 |
CN111972672A (zh) * | 2020-08-25 | 2020-11-24 | 黑龙江省完达山乳业股份有限公司 | 一种具有增加肌肉功能的组合物及其应用 |
CN112155057A (zh) * | 2020-08-25 | 2021-01-01 | 石家庄君乐宝乳业有限公司 | 高蛋白增肌稠厚型调制乳粉及其制备方法 |
CN115177000A (zh) * | 2021-04-07 | 2022-10-14 | 陕西罗麻丹医药有限公司 | 一种改善老年肌少症的粉剂及其制备方法 |
WO2022226828A1 (zh) * | 2021-04-28 | 2022-11-03 | 益达生医股份有限公司 | 供改善肌少症的营养组合物及其用途 |
CN113398144A (zh) * | 2021-07-27 | 2021-09-17 | 大连双迪科技股份有限公司 | 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用 |
CN113398144B (zh) * | 2021-07-27 | 2022-04-01 | 陈玉松 | 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用 |
CN114209066A (zh) * | 2021-12-08 | 2022-03-22 | 国珍健康科技(北京)有限公司 | 一种用于改善肌肉衰减的组合物及其制备方法和应用 |
CN114304287A (zh) * | 2022-01-06 | 2022-04-12 | 江南大学 | 肌肉衰减综合征医学配方食品中用的脂肪组件、制备方法及应用 |
CN114304287B (zh) * | 2022-01-06 | 2023-01-24 | 江南大学 | 肌肉衰减综合征医学配方食品中用的脂肪组件、制备方法及应用 |
CN114431380A (zh) * | 2022-02-25 | 2022-05-06 | 广东君悦营养医学有限公司 | 一种适用于肌肉衰减综合症的蛋白水及其制备方法 |
CN114680339A (zh) * | 2022-04-12 | 2022-07-01 | 天津医科大学 | 一种改善肌肉衰减延缓衰老的营养补充剂及其应用 |
CN116473236A (zh) * | 2023-04-19 | 2023-07-25 | 安徽昊天生物科技有限公司 | 一种运动后恢复型运动营养食品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108618129A (zh) | 肌肉衰减综合症专用型临床营养配方及其制备方法 | |
US20210352948A1 (en) | Composition for treating diabetes based on traditional Chinese medicine nutritional therapy and application thereof | |
CN109645320A (zh) | 一种轻断食全营养配方可冲泡即食棒及其制备方法 | |
CN107319525A (zh) | 一种减肥减脂专用型临床营养配方及其制备方法 | |
CN106983136A (zh) | 一种产褥期调理专用型临床营养配方及其制备方法 | |
CN106983151A (zh) | 一种炎性肠病专用型临床营养配方及其制备方法 | |
CN111972672A (zh) | 一种具有增加肌肉功能的组合物及其应用 | |
CN107440120A (zh) | 一种儿童挑食偏食厌食专用型临床营养配方及其制备方法 | |
CN108077911A (zh) | 一种癫痫患者专用型临床营养配方及其制备方法 | |
CN103652862B (zh) | 一种具有排毒减肥功能的保健食品及其制备方法 | |
CN101473953A (zh) | 净血排毒组合食品及其加工方法和应用 | |
CN103719282A (zh) | 一种中老年配方奶粉 | |
CN101579120A (zh) | 一种具有减肥功能的营养食品及其制备方法 | |
CN112118748A (zh) | 水解豌豆蛋白基营养组合物 | |
CN110973613A (zh) | 一种适用于减重人群食用的植物复合粉组合物、适用于减重人群食用的产品和应用 | |
CN110301629A (zh) | 一种肿瘤患者全营养固体饮料及其制备方法 | |
KR20170133650A (ko) | 기능성 노견죽 및 그 제조방법 | |
CN110074397A (zh) | 一种儿童生长发育专用型临床营养配方及其制备方法 | |
CN108669540A (zh) | 脑卒中专用型临床营养配方及其制备方法 | |
CN108013452A (zh) | 一种产后腹胀气专用型临床营养配方及其制备方法 | |
CN108719984A (zh) | 一种针对痛风人群的代餐营养棒及其制备方法 | |
CN108703365A (zh) | 蛋白质过敏专用型临床营养配方及其制备方法 | |
CN104855997A (zh) | 骨质疏松非全营养配方食品 | |
CN106418501A (zh) | 一种具有减肥功能的保健食品 | |
CN109329902A (zh) | 一种儿童白血病专用型临床营养配方及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181009 |
|
RJ01 | Rejection of invention patent application after publication |